FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

Share this content:
FDA Panel Has Tie Vote on New Type 1 Diabetes Drug
FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

FRIDAY, Jan. 18, 2019 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel vote on whether to recommend approval of the first oral medication for type 1 diabetes ended in an 8-8 tie Thursday.

Despite that result, the FDA is expected to decide by the end of March whether the drug -- sotagliflozin, brand name Zynquista -- should be made available in the United States, The New York Times reported. The drug, used along with insulin, is a once-daily pill meant to help type 1 diabetes patients manage their blood glucose levels.

Some of the advisory panel members voted against Zynquista because it carries an increased risk for diabetic ketoacidosis, The Times reported.

Drug makers Sanofi and Lexicon Pharmaceuticals said they will continue to work with the FDA through the review process for the drug.

The New York Times Article

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA: Gout Drug Uloric Increases Risk of Death

FDA: Gout Drug Uloric Increases Risk of Death

Medication is associated with increased risk of heart-related death and death from all causes

Since Early 2000s, Overdose Death Rates Are Highest in U.S.

Since Early 2000s, Overdose Death Rates Are Highest ...

U.S. was not an outlier in terms of drug overdose mortality prior to the early 2000s

National Health Spending Set to Increase 5.5 Percent Annually

National Health Spending Set to Increase 5.5 Percent ...

Long-observed demographic and economic factors expected to drive growth in health spending

is free, fast, and customized just for you!




Already a member?

Sign In Now »